Elligo targets gender equality in trials: ‘There is still a long way to go’

By Flora Southey contact

- Last updated on GMT

(Image: Getty/Talaj)
(Image: Getty/Talaj)

Related tags: CRO

Elligo Health Research has partnered with Women’s Health USA to help improve female patient numbers in clinical trials.

According to the agreement, women seeing physicians affiliated with Women’s Health USA – a national network of women’s health, obstetrics and gynaecology practices – will have access to Elligo’s ‘Research Ready’ network.

The firm employs its ‘Goes Direct’ approach​ at these sites, to provide physicians with the staff, procedures, technology, and infrastructure required to conduct trials.

“Our community of Research Ready sites, including those participating through our Women’s Health USA partnership, allows us to quickly identify protocol-matching patients for study participation, which not only gets studies started sooner, but helps sponsors bring drugs to market faster,” ​Elligo president Chad Moore told us.

“Additionally, the data collected will come from a more diversified patient pool, potentially bringing light to a wider range of outcomes,” ​he added.

According to Moore, taking clinical research directly to physicians and patients will also help contract research organisations (CROs) save time and resources via improved patient recruitment, randomization and retention.

A female focus

The partnership will not only improve female access to therapies, but it “keeps women under the care of their trusted physician and makes participation more convenient by bringing these studies closer to home,” ​Moore told us.

It is important clinical research be specifically targeted to women, he added. There are a number of indications – including endometriosis, uterine fibroids and certain infections – that impact only women. In recent years, we have seen an increase in clinical research activity for these types of studies.”

While Moore acknowledged recent improvements in female patient recruitment numbers, and women-targeted research, “There is still a long way to go to ensure the differences in gender are accounted for,” ​he said.

“More work is certainly needed to better understand how men and women vary in the absorption, distribution, metabolism and excretion of medication, as there could potentially be underlying health and safety concerns,” ​he added.

The agreement expands on a partnership​ between Elligo and Consortia Health, agreed in June 2017, which saw the firm’s ‘Goes Direct’ approach extend to Consortia’s women’s clinic network in the US.

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more